Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 18,220,000 shares, a decrease of 5.2% from the October 15th total of 19,220,000 shares. Currently, 17.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,810,000 shares, the days-to-cover ratio is presently 4.8 days.
Analyst Upgrades and Downgrades
Several analysts have issued reports on ESPR shares. StockNews.com started coverage on shares of Esperion Therapeutics in a report on Thursday, October 5th. They issued a “hold” rating on the stock. Needham & Company LLC reduced their price target on shares of Esperion Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Esperion Therapeutics in a report on Monday, November 13th. Finally, Northland Securities raised shares of Esperion Therapeutics from an “under perform” rating to a “market perform” rating in a research note on Tuesday, August 1st. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Esperion Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $10.75.
Hedge Funds Weigh In On Esperion Therapeutics
Esperion Therapeutics Stock Up 7.2 %
NASDAQ:ESPR opened at $1.19 on Friday. The company has a market cap of $135.32 million, a P/E ratio of -0.50 and a beta of 0.30. Esperion Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $8.87. The firm’s 50 day moving average is $0.99 and its two-hundred day moving average is $1.32.
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. The company had revenue of $33.97 million for the quarter, compared to analysts’ expectations of $30.84 million. During the same period in the prior year, the business earned ($0.81) EPS. Research analysts forecast that Esperion Therapeutics will post -1.99 earnings per share for the current fiscal year.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
- Five stocks we like better than Esperion Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- MarketBeat Week in Review – 11/13 – 11/17
- Breakout Stocks: What They Are and How to Identify Them
- 3 large caps with red hot RSIs with upside
- Compound Interest and Why It Matters When Investing
- Johnson Controls International: Nothing but upside for investors
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.